New Drug Uses Enzyme Blocking To Swiftly Remove Fat From Arteries!
Researchers from the University of Aberdeen are testing a new drug intended for breast cancer and diabetes treatment. The drug called Trodusquemine turns out to have reversing effects on the piling up of fatty plaques in arteries. It’s said to ‘melt away’ fat inside arteries by stopping a key enzyme normally found in people with diabetes and heart problems.
Pre-clinical trials on mice show that just a single dose of the drug completely reversed the effects of a disease that causes a host of heart problems such as strokes and heart attacks.
One of the associated conditions that can result in a stroke or heart attack is atherosclerosis – the build-up of fatty material inside the arteries. Fatty material can aggregate in certain places up to a point when your arteries become so narrow that not enough blood can pass through. It is the most common precursor to heart attacks and strokes.
Atherosclerosis generally starts when a person is young and worsens with age. Almost all people are affected to some degree by the age of 65. It is the number one cause of death and disability in the developed world.
In pre-clinical tests, mice with set-in atherosclerosis – mimicking what happens in humans – had less fatty plaques in their arteries whether they had regular doses over time or just a single dose of Trodusquemine.
Professor Mirela Delibegovic and Dr Dawn Thompson from the University of Aberdeen’s Institute of Medical Sciences who led the study said: “All humans have some level of atherosclerosis. As you age, you start to develop these fatty streaks inside your arteries. It is a big problem for people who are overweight or have underlying cardiovascular conditions…”
Trodusquemine affects an enzyme called PTP1B, deactivating it. The enzyme is largely present in people with obesity or diabetes and conditions involving prolonged inflammation such as sepsis, inflamed diabetic foot ulcers and allergic lung inflammation. The researchers found that it also stimulated the action of another protein (AMPK), which effectively mimics exercise and reduces chronic inflammation. It has already been shown to be effective with diabetes and breast cancer patients, but this is the first time the drug has been shown to have benefits for long-term cardiovascular disease.
“… this is the first time it has been used in models of atherosclerosis. These have only been tested at pre-clinical level, in mice, so far – but the results were quite impressive and showed that just a single dose of this drug seemed to completely reverse the effects of atherosclerosis. The next step is to test the ability of this drug to improve outcomes in human patients with developed atherosclerosis and cardiovascular disease.”